List of Excipients in Branded Drug BOSULIF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	BOSULIF	bosutinib	0069-0135	CELLULOSE, MICROCRYSTALLINE
Pfizer Laboratories Div Pfizer Inc	BOSULIF	bosutinib	0069-0135	CROSCARMELLOSE SODIUM
Pfizer Laboratories Div Pfizer Inc	BOSULIF	bosutinib	0069-0135	FERRIC OXIDE YELLOW
Pfizer Laboratories Div Pfizer Inc	BOSULIF	bosutinib	0069-0135	MAGNESIUM STEARATE
Pfizer Laboratories Div Pfizer Inc	BOSULIF	bosutinib	0069-0135	POLOXAMER 188
Pfizer Laboratories Div Pfizer Inc	BOSULIF	bosutinib	0069-0135	POLYETHYLENE GLYCOL 3350

Bosulif Excipient Strategy and Commercial Opportunities for Bosutinib

Last updated: August 8, 2026

Bosulif is Pfizer’s oral bosutinib product for Philadelphia chromosome-positive chronic myeloid leukemia. Its commercial formulation is a conventional immediate-release, film-coated tablet containing bosutinib monohydrate and a compact excipient system built around microcrystalline cellulose, croscarmellose sodium, poloxamer 188, povidone, and magnesium stearate. The main formulation constraint is bosutinib’s food-dependent exposure and limited aqueous solubility. Commercial opportunities therefore center on lower-cost generic tablets, improved food-independent delivery, dose-flexible products, and reformulations that reduce gastrointestinal tolerability problems.

The strongest commercial position remains the branded product’s clinical familiarity and regulatory history. The main erosion risk is ordinary small-molecule generic entry rather than biosimilar competition. Any differentiated reformulation must overcome the established 100 mg, 400 mg, and 500 mg tablet presentation, the requirement to administer Bosulif with food, and patent or regulatory protections covering bosutinib, formulations, and methods of use.

What is Bosulif and how is bosutinib formulated?

Bosulif contains bosutinib, a tyrosine kinase inhibitor that inhibits BCR::ABL1 and Src-family kinases. The FDA approved Bosulif in 2012 for adults with Philadelphia chromosome-positive chronic myeloid leukemia in specified treatment settings and later expanded the label to include newly diagnosed chronic-phase disease.[1]

Bosulif dosage forms and strengths

Product attribute	Bosulif specification
Active ingredient	Bosutinib monohydrate
Dosage form	Immediate-release film-coated tablet
Strengths	100 mg, 400 mg, 500 mg
Administration	Oral; tablets swallowed whole
Food instruction	Take with food
Commercial manufacturer	Pfizer
Primary disease area	Ph+ chronic myeloid leukemia
Main formulation issue	Food-dependent absorption and gastrointestinal tolerability

The FDA prescribing information identifies the tablet core as containing microcrystalline cellulose, croscarmellose sodium, poloxamer 188, povidone, and magnesium stearate. The film coating contains hypromellose, titanium dioxide, triacetin, and colorants that vary by strength.[1]

The excipient architecture is conventional:

• Microcrystalline cellulose provides bulk and compaction.
• Croscarmellose sodium promotes tablet disintegration.
• Povidone functions primarily as a binder.
• Poloxamer 188 provides surfactant activity and may support wetting of the poorly water-soluble active ingredient.
• Magnesium stearate acts as a lubricant.
• Hypromellose forms the film coating.
• Triacetin acts as a coating plasticizer.
• Titanium dioxide and iron oxide colorants provide product identification.

The formulation does not use an advanced lipid, amorphous solid dispersion, cyclodextrin, or nanoparticle delivery platform in the approved product.

What excipient strategy does Bosulif use?

Bosulif uses a low-complexity immediate-release strategy rather than a modified-release platform. The excipient selection supports tablet manufacturability and disintegration while using poloxamer 188 to improve wetting of bosutinib.

Solubility and absorption constraints

Bosutinib has limited water solubility and clinically meaningful food effects. The FDA label reports higher exposure when bosutinib is administered with food than when administered in the fasted state.[1] This creates three formulation objectives:

1. Maintain adequate dissolution across gastrointestinal conditions.
2. Reduce the magnitude of food-dependent exposure.
3. Preserve dose proportionality and bioequivalence across multiple tablet strengths.

The food requirement is commercially important. A product that delivers consistent exposure without a meal could improve adherence, reduce administration complexity, and support differentiation from standard generic bosutinib.

Excipient functions and development implications

Excipient or component	Functional role	Commercial relevance
Microcrystalline cellulose	Filler and compression aid	Widely available; low barrier to generic manufacture
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup
Poloxamer 188	Wetting and solubilization aid	Potentially important for dissolution control
Povidone	Binder	Supports granulation and tablet strength
Magnesium stearate	Lubricant	Requires control because excess can impair dissolution
Hypromellose	Film former	Standard coating material
Triacetin	Plasticizer	Supports coating flexibility
Titanium dioxide and iron oxides	Colorants	Product identification and strength differentiation

The use of widely available excipients limits the standalone defensibility of the Bosulif excipient system. A generic manufacturer can generally select alternative inactive ingredients if the finished product satisfies applicable FDA quality, bioequivalence, labeling, and inactive-ingredient requirements.

What formulations are protected by Bosulif-related intellectual property?

Bosulif’s commercial protection can include compound patents, formulation patents, polymorph or salt patents, manufacturing patents, and method-of-use patents. The approved label alone does not identify the full scope of Pfizer’s intellectual-property position.

Compound and formulation protection

For a small-molecule product such as bosutinib, the principal patent categories are:

• The bosutinib chemical compound and related analogs.
• Bosutinib salts, solvates, or crystalline forms.
• Pharmaceutical compositions containing bosutinib.
• Methods of treating Ph+ CML.
• Dosing schedules and treatment-line restrictions.
• Processes for preparing bosutinib or intermediates.
• Use of bosutinib with food or in specific patient populations, where claimed.

Formulation claims can be commercially relevant even when the active-ingredient patent has expired. A formulation patent may cover a specific dissolution profile, excipient combination, particle-size distribution, solid form, or manufacturing process. Such claims do not automatically prevent all generic entry. Their practical effect depends on Orange Book listing, claim scope, enforceability, and whether an ANDA applicant makes a Paragraph IV certification.

Orange Book status

Bosulif is an FDA-approved small-molecule drug listed in the FDA Orange Book. Orange Book entries can include patents claiming the drug substance, drug product, or approved method of use.[2]

The key diligence questions are:

• Which bosutinib patents are currently listed?
• Which listed claims cover the approved 100 mg, 400 mg, and 500 mg tablets?
• Which patents expire before or after regulatory exclusivity?
• Are any listed patents subject to pediatric extensions?
• Have generic applicants submitted Paragraph IV certifications?
• Have Pfizer or related entities filed infringement suits within the 45-day statutory period?

Patent expiry should be determined from the current Orange Book patent table and individual patent records. Patent term adjustment, terminal disclaimers, pediatric extensions, reexamination, and post-grant proceedings can change the effective date.

When does Bosulif lose exclusivity?

Bosulif’s five-year new chemical entity exclusivity began with the 2012 FDA approval and prevented submission of an ANDA relying on the reference product during the NCE period, subject to statutory exceptions. That exclusivity period has expired.[1,3]

The present commercial issue is patent-based generic entry rather than FDA exclusivity. The relevant timeline is:

Milestone	Commercial effect
2012 initial FDA approval	Established the reference product and five-year NCE exclusivity
2017 and later label expansions	Increased the addressable Ph+ CML population and created additional method-of-use considerations
Patent expiry dates	Determine the earliest unblocked generic launch opportunity
Paragraph IV filing	Can trigger patent litigation and a potential 30-month stay
First eligible ANDA approval	May create commercial launch opportunity, subject to patents and settlements
Pediatric extension, if applicable	Can extend certain protections by six months

Bosulif does not have biologic exclusivity. Biosimilar rules therefore do not apply.

Which companies are challenging Bosulif?

Generic-drug companies are the relevant challengers. The potential applicant pool includes manufacturers that already commercialize oncology tablets or have established ANDA portfolios in kinase inhibitors.

A Paragraph IV challenge would require the applicant to certify that a listed patent is invalid, unenforceable, or will not be infringed. Pfizer could file an infringement action within 45 days of receiving notice. That action could trigger a statutory stay of FDA approval for up to 30 months, subject to court decisions and statutory exceptions.[3]

A reliable public assessment of challenger identity requires the current FDA Paragraph IV database, Orange Book records, district-court dockets, and any settlement filings. The presence of an ANDA filing does not establish that a generic has FDA approval or a launch right.

What generic launch scenarios exist?

The most likely scenarios are:

1. Non-challenge launch after patent expiry. The generic waits for all relevant listed patents to expire.
2. Paragraph IV litigation. The applicant seeks approval before patent expiry and accepts litigation risk.
3. Section viii carve-out. The applicant removes a patented method of use from its labeling if the remaining indications support approval.
4. Settlement with delayed entry. The applicant receives a negotiated launch date, potentially with a license or other restrictions.
5. At-risk launch. The applicant launches before final resolution, exposing itself to damages or injunction risk.

For Bosulif, the most commercially important distinction is whether generic applicants can enter with a standard immediate-release tablet while carving out one or more patented indications. CML products often have overlapping treatment-line indications, making label carve-outs more complex than in products with a single narrow use.

How strong is the Bosulif patent estate?

The patent estate is strongest when it combines an enforceable compound or solid-form patent with approved method-of-use claims and a commercially difficult formulation or manufacturing process. It is weaker when protection depends primarily on broad composition claims that can be designed around with conventional excipients.

Strength indicators

Patent-estate factor	Effect on Bosulif generic risk
Active compound patent remains in force	High barrier if valid and infringed
Narrow formulation patent	Moderate barrier; design-around risk is higher
Method-of-use patent	May permit label carve-outs
Manufacturing patent	Can be important if the process is difficult to replicate
Multiple independent patents	Increases litigation complexity
Patent expiry near expected approval date	Raises launch uncertainty
No enforceable listed patent	High generic-entry risk

The excipient system itself is unlikely to create a durable commercial moat unless a new formulation produces a measurable clinical or regulatory advantage. A generic company can often replace poloxamer 188, change the binder system, or use a different granulation process if dissolution and bioequivalence remain acceptable.

What commercial opportunities exist for bosutinib excipients?

The largest opportunity is not supplying a single commodity excipient. It is providing a formulation platform that solves a specific bosutinib performance problem.

Food-independent bosutinib formulation

A formulation that reduces or eliminates the food effect could support:

• Improved adherence.
• Simpler patient instructions.
• Lower variability in exposure.
• Potentially better use in patients with poor appetite or gastrointestinal disease.
• A differentiated lifecycle-management product.

Possible technologies include amorphous solid dispersions, lipid-based systems, particle engineering, surfactant combinations, and precipitation-inhibiting polymers. Each approach would require comparative dissolution, food-effect, stability, and clinical or pharmacokinetic evidence.

Lower-dose and dose-flexible tablets

Bosulif dosing is adjusted for tolerability, hepatic or renal impairment, drug interactions, and treatment response. Commercial opportunities include:

• 50 mg tablets for titration.
• Combination packs for dose escalation.
• Scored tablets if technically and regulatorily appropriate.
• Unit-dose packaging for adherence and dispensing control.

A lower-strength product could reduce tablet splitting and improve dose management. Its value would depend on label support, payer coverage, manufacturing economics, and patent status.

Gastrointestinal-tolerability strategy

Diarrhea, nausea, vomiting, abdominal pain, and other gastrointestinal adverse events are clinically relevant to bosutinib treatment.[1] Excipients cannot be assumed to eliminate active-drug toxicity, but a better-dispersing or lower-peak-exposure formulation could be evaluated for tolerability.

Potential development targets include:

• Lower peak concentration without reducing total exposure.
• More consistent dissolution across fed and fasted conditions.
• Reduced local gastrointestinal concentration.
• A formulation compatible with food-independent administration.

These claims would require clinical evidence. Dissolution improvement alone would not establish a tolerability benefit.

Pediatric and special-population products

Pediatric CML is a limited but strategically relevant market. Bosutinib has pediatric labeling in the United States, creating potential demand for age-appropriate dosage forms.[1] Commercial formats could include:

• Smaller tablets.
• Dispersible tablets.
• Oral granules.
• Oral suspension or reconstitutable powder.
• Flexible-dose packaging.

A liquid formulation would introduce new excipient risks, including sedimentation, chemical stability, microbial control, taste masking, and dosing-device accuracy. Taste-masking polymers, sweeteners, suspending agents, and preservatives would require pediatric safety review.

How does Bosulif compare with competing CML drugs?

Bosutinib competes with other BCR::ABL1 tyrosine kinase inhibitors, including imatinib, dasatinib, nilotinib, ponatinib, and asciminib. The commercial opportunity for excipient innovation depends on the clinical segment.

Drug	Manufacturer or originator	Formulation opportunity relative to bosutinib
Bosulif	Pfizer	Food-effect reduction, GI tolerability, dose flexibility
Gleevec	Novartis	Mature generic market; low branded reformulation opportunity
Sprycel	Bristol Myers Squibb	Tablet competition and established generic exposure
Tasigna	Novartis	More restrictive food administration creates adherence opportunity
Iclusig	Takeda	High-risk disease positioning; smaller but differentiated population
Scemblix	Novartis	Newer product with differentiated mechanism and lifecycle protection

Asciminib has a different mechanism and may reduce long-term dependence on older TKIs in some treatment settings. That competitive shift limits the value of a bosutinib reformulation unless it improves tolerability, administration convenience, or access sufficiently to defend market share.

What manufacturing and IP barriers affect bosutinib products?

Bosutinib manufacturing does not appear to require a biologic-scale process or complex sterile delivery system. The primary technical barriers are solid-state control, dissolution reproducibility, impurity management, and tablet performance.

Manufacturing barriers

A commercial developer must control:

• Bosutinib particle size and morphology.
• Polymorphic or solvate behavior.
• Wetting and dispersion.
• Granulation endpoint.
• Lubrication time and magnesium stearate distribution.
• Tablet hardness and disintegration.
• Film-coating uniformity.
• Dissolution across pH conditions.
• Stability under temperature and humidity stress.

Poloxamer 188 can improve wetting but may introduce risks involving content uniformity, phase behavior, and dissolution sensitivity. A substitute surfactant or polymer can reduce dependence on the reference formulation but may create new regulatory and stability burdens.

Geographic coverage

U.S. commercial risk is driven by FDA approval, Orange Book patents, and U.S. litigation. Europe, Canada, Japan, and emerging markets follow separate patent, regulatory, and pricing frameworks. A product can face early generic competition in one jurisdiction while remaining protected in another.

For licensing, the most valuable rights may include:

• U.S. formulation patents.
• European composition or process patents.
• Regional manufacturing rights.
• Technology-transfer rights for a food-independent formulation.
• Pediatric dosage-form rights.
• Rights to supply Pfizer or generic manufacturers with specialized excipients.

What is the revenue exposure from Bosulif generic entry?

Bosulif revenue is exposed to the standard small-molecule erosion pattern: relatively limited loss before the first generic, followed by price compression and share loss after multiple ANDA approvals. The degree of erosion depends on the number of approved generics, authorized-generic strategy, payer substitution, and the availability of competing TKIs.

Revenue sensitivity is highest in:

• Newly diagnosed chronic-phase CML.
• Stable patients maintained on bosutinib.
• Markets with automatic generic substitution.
• Treatment settings without a strong preference for newer agents.
• Regions where Pfizer lacks contracting leverage.

Revenue protection is stronger where a differentiated formulation has separate patent protection, clinical evidence, or a meaningful convenience advantage. A formulation change without a new indication, lower toxicity, or easier administration is unlikely to support a large premium after generic entry.

Key Takeaways

• Bosulif is an immediate-release bosutinib tablet containing conventional excipients and poloxamer 188 as a wetting or solubilization aid.
• The main formulation constraint is food-dependent exposure combined with gastrointestinal tolerability concerns.
• The highest-value lifecycle opportunity is a food-independent, more consistent bosutinib formulation.
• Lower-strength tablets and pediatric-friendly dosage forms offer secondary commercial opportunities.
• Bosulif faces generic rather than biosimilar competition.
• Paragraph IV activity, Orange Book listings, patent expiry, and settlement terms determine the actual generic-entry date.
• Conventional excipients offer limited standalone IP protection because generic manufacturers can usually design around them.
• Solid-state control, dissolution performance, and manufacturing reproducibility are the principal technical barriers.
• Asciminib and other CML therapies constrain the long-term value of a bosutinib reformulation.
• A commercially defensible reformulation requires clinical or administration benefits, not only a different excipient list.

FAQs

Can a generic bosutinib tablet use different excipients from Bosulif?

Yes. An ANDA applicant generally can use different inactive ingredients if the product meets FDA requirements for quality, safety, dissolution, bioequivalence, and labeling.

Does Bosulif require a special controlled-release excipient system?

No. The approved product is an immediate-release film-coated tablet. Its formulation challenge is solubility and food-dependent absorption rather than sustained release.

Is poloxamer 188 essential to bosutinib performance?

Poloxamer 188 is part of the approved Bosulif formulation and likely supports wetting. It is not necessarily required in every generic formulation if an alternative excipient system delivers equivalent quality and bioavailability.

Could a liquid bosutinib product create new patent value?

Yes. A stable, palatable pediatric liquid or dispersible dosage form could support formulation patents and commercial differentiation, provided the product meets clinical, stability, and regulatory requirements.

Does a bosutinib formulation patent automatically block generic approval?

No. Blocking effect depends on whether the patent is properly listed, whether the generic product infringes the claims, whether the applicant files a Paragraph IV certification, and how litigation or settlement affects approval.

References

1. U.S. Food and Drug Administration. (2023). Bosulif (bosutinib) prescribing information. Pfizer Laboratories. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulations and patent certifications. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda-forms-and-submission-requirements